Marginal Zone Lymphoma Clinical Trials 2023

What are the top hospitals conducting marginal zone lymphoma research?

In the realm of clinical trials for marginal zone lymphoma, several hospitals are making significant strides in research and treatment options. Starting in Florham Park, New jersey, Summit Medical Group stands out with two active trials dedicated to this rare form of lymphoma. Although their overall contribution is still growing, they recorded their first trial for marginal zone lymphoma as recently as 2022. On the other side of the country in Houston, Texas, Md Anderson Cancer Center has also emerged as a leading institution with two ongoing trials and a total of two completed studies since embarking on their first trial in 2021.

Meanwhile, Asclepes Research Centers located in Weeki Wachee have made notable progress themselves by conducting two active marginal zone lymphoma trials and an additional pair of completed investigations since recording their inaugural trial back in 2017. The University of Washington - Seattle Cancer Care Alliance shares this accomplishment with them; boasting two ongoing clinical tests alongside a history marked by successful completion of two previous studies starting from that same year.

Another valuable contributor to marginal zone lymphoma research can be found at Clinical Research Alliance situated at New Hyde Park—a facility engaged in two current clinical trials while also having conducted one study previously; all three endeavors representing advancements made after initiating their record-breaking investigation on this particular condition during 2017.

These hospitals signify not only dedication but also remarkable collaboration within the medical community towards unraveling the mysteries surrounding marginal zone lymphoma. Each effort brings us closer to better understanding this complex disease and developing more effective treatments that offer hope to individuals diagnosed with it around the world

Which are the best cities for marginal zone lymphoma clinical trials?

When it comes to marginal zone lymphoma clinical trials, several cities have emerged as top contenders. Houston, Texas, New york City, Miami, Florida, Detroit, Michigan, and Whittier, California are leading the way with their active trials. In Houston and New York City alone there are 4 ongoing studies each exploring treatments like Ultra Low Dose 4 Gy Radiation, Zanubrutinib, tafasitamab among others. Miami has 3 active trials focusing on Parsaclisib and Loncastuximab tesirine 150 µg/Kg. Similarly in Detroit and Whittier there are also 3 active trials each investigating various treatment options for marginal zone lymphoma. These cities offer patients access to cutting-edge research that could potentially transform the landscape of care for this specific type of lymphoma.

Which are the top treatments for marginal zone lymphoma being explored in clinical trials?

Clinical trials are actively exploring several promising treatments for marginal zone lymphoma. These include:

• Ultra Low Dose 4 Gy Radiation: Currently being tested in one active trial and is the first of its kind listed in 2023.
• Loncastuximab tesirine 150 µg/Kg: Under investigation in one ongoing trial since its introduction in 2022.
• Zanubrutinib: Showing promise with seven all-time clinical trials for marginal zone lymphoma, including one currently underway, since it was first listed back in 2016.
• Mosunetuzumab: Making waves as a potential treatment option with two previous trials and an ongoing study initiated in 2022.
• Tafasitamab: Also undergoing evaluation through a single active clinical trial after its initial listing as a potential treatment option for marginal zone lymphoma patients in 2021.

These exciting developments offer hope to individuals battling this form of lymphoma, bringing us closer to more effective therapies.

What are the most recent clinical trials for marginal zone lymphoma?

Recent clinical trials offer promising advancements in the treatment of marginal zone lymphoma. One notable study explores the efficacy of ultra-low dose 4 Gy radiation, providing a potential alternative for patients. Additionally, a combination therapy involving obinutuzumab and glofitamab shows promise in addressing this specific type of lymphoma. Another trial focuses on evaluating mosunetuzumab as a treatment option, while loncastuximab tesirine demonstrates its potential benefits through targeted therapy. Furthermore, zanubrutinib is being investigated in phase 3 to assess its effectiveness against marginal zone lymphoma. These ongoing studies hold great potential for improved outcomes and expanded therapeutic options for individuals living with this condition

What marginal zone lymphoma clinical trials were recently completed?

Several clinical trials investigating potential treatments for marginal zone lymphoma have recently been completed, showcasing the commitment of researchers to combat this form of cancer. In November 2020, a trial sponsored by the University of Colorado, Denver concluded its investigation into Ublituximab. Additionally, BeiGene wrapped up their trial on Zanubrutinib in February 2019. Another noteworthy trial was conducted by TG Therapeutics, Inc., completing their study on Umbralisib in November 2017. These recent advancements provide valuable insights and bring hope to patients affected by marginal zone lymphoma.